Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research VEGF 

    • The role of VEGF across tumor types 

    • VEGF in colorectal cancer 

    • VEGF and prognosis 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
    • Research BRAF
    • Research HDIs
    • Research HER Pathways
    • Research MET
    • Research VEGF
      • Why is the VEGF ligand essential throughout tumor development?
      • What are the strategies for inhibiting the VEGF pathway?
      • What are the effects of direct VEGF ligand inhibition?
      • Why is continued VEGF inhibition important?
      • Why do tumors progress?
      • The role of VEGF across tumor types
        • VEGF in lung cancer
        • VEGF in colorectal cancer
          • Evidence of VEGF expression
          • VEGF and prognosis
            • Survival
            • Increased risk of relapse
            • Metastasis
            • Tumor invasion/lymph node involvement
          • VEGF as a predictive factor
          • Summary
        • VEGF in renal cell carcinoma
        • VEGF in glioblastoma
        • VEGF in ovarian cancer
        • VEGF in bladder cancer
        • VEGF in gastric cancer
        • VEGF in multiple myeloma
        • VEGF in pancreatic cancer
      • Slide decks and videos
      • Glossary
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • Colorectal Cancer
      • Colorectal Cancer
    • Glioblastoma
      • Glioblastoma
    • Lung Cancer
      • Lung Cancer
    • Ovarian Cancer
      • Ovarian Cancer
    • Pancreatic Cancer
      • Pancreatic Cancer
    • Renal Cell Carcinoma
      • Renal Cell Carcinoma
  • Molecular Causes of Cancer
    • Angiogenesis
      • Inducing angiogenesis
    • Growth Signaling
      • Evading growth suppressors
    • Tissue Invasion and Metastasis
      • Activating invasion and metastasis
  • Biological Pathways
    • Angiogenic Signaling
      • Angiogenic Signaling
    • Apoptotic Signaling
      • Apoptosis
    • Bcell Surface Proteins
      • B-cell Surface Proteins
    • HER Signaling
      • HER Signaling
    • MAPK Signaling
      • MAPK Signaling
  • Therapeutic Targets
    • BCL-2
      • Bcl-2
    • HER1
      • HER1
    • HER2
      • HER2
    • HER3
      • HER3
    • HER4
      • HER4
    • VEGF
      • VEGF
  • Clinical Trials
    • Colorectal Cancer
      • Colorectal Cancer
  • Future Directions
    • Antibody-Drug conjugates
      • VEGF expression in gastric cancer
      • HER Signaling
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Serum VEGF as a clinical marker
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Glycoengineered Antibodies
      • VEGF expression in gastric cancer
      • HER Signaling
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Serum VEGF as a clinical marker
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Non-Antibody Biologics
      • Apoptosis
      • VEGF expression in gastric cancer
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Serum VEGF as a clinical marker
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Targeted Small Molecules
      • Apoptosis
      • Resisting apoptosis
      • VEGF expression in gastric cancer
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MAPK Signaling
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Serum VEGF as a clinical marker
      • PI3K/Akt/mTOR Signaling
      • Slide decks and videos
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Traditional Monoclonal Antibodies
      • Anti-EGFL7
      • B-cell Surface Proteins
      • Glossary
      • VEGF expression in gastric cancer
      • HER Signaling
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Serum VEGF as a clinical marker
      • Angiogenic Signaling
      • Slide decks and videos
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma

Video

Full VEGF & angiogenesis

View video now

Slides

The role of VEGF in colorectal cancer (CRC)

View Slides

Links

  • VEGF in lung cancer
  • VEGF in RCC
  • VEGF in GBM
  • VEGF in ovarian cancer
Share

VEGF and prognosis in colorectal cancer

Evidence from numerous studies and analyses points to vascular endothelial growth factor (VEGF) and angiogenesis as prognostic factors in colorectal cancer. For information on a particular outcome that has been correlated with VEGF expression, click on the links in the table below.

Outcome Study Type and Size Source
Poor survival Clinical study (N=60)

Meta-analysis of 27 studies
Ishigami et al, Br J Cancer, 19981

Des Guetz et al, Br J Cancer, 20062
Increased risk of relapse Meta-analysis of 27 studies Des Guetz et al, Br J Cancer, 20062
Metastasis Clinical study (N=133)

Clinical study (N=60)

Clinical study (N=31)
Tanigawa et al, Cancer Res, 19973

Ishigami et al, Br J Cancer, 19981

Kuramochi et al, Clin Cancer Res, 20064
Tumor invasion
and lymph node
involvement
Clinical study (N=72)

Clinical study (N=90)
Ottaiano et al, Clin Cancer Res, 20065

Saad et al, Mod Pathol, 20066
References:
1.
Ishigami SI, Arii S, Furutani M, et al. Br J Cancer. 1998;78:1379-1384. PMID: 9823983
2.
Des Guetz G, Uzzan B, Nicolas P, et al. Br J Cancer. 2006;94:1823-1832. PMID: 16773076
3.
Tanigawa N, Amaya H, Matsumura M, et al. Cancer Res.
1997;57:1043-1046. PMID: 9067267
4.
Kuramochi H, Hayashi K, Uchida K, et al. Clin Cancer Res. 2006;12:29-33. PMID: 16397020
5.
Ottaiano A, Franco R, Talamanca AA, et al. Clin Cancer Res. 2006;12:2795-2803. PMID: 16675573
6.
Saad RS, Kordunsky L, Liu YL, Denning KL, Kandil HA, Silverman JF. Mod Pathol. 2006;19:1317-1323. PMID: 16799477
 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: Survival »

© 2011 Genentech USA, Inc. All rights reserved